18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06503146

Title field or adapter rule

{'original_value': '18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:21.563681+00:00

Published At

2026-10-29T00:00:00+00:00

Record Updated At

2026-10-29

Source Retrieved At

2026-10-31T22:18:28.651351+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Sarcoma", "Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)", "Mesothelioma", "Pheochromocytoma/Paraganglioma (PPGL)", "Pancreatic Ductal Adenocarcinoma", "Ovarian Cancer", "Hepatocellular Carcinoma", "Gastric Cancer", "Cholangiocarcinoma", "Bladder Cancer"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-29", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06503146"

protocolSection.identificationModule.officialTitle

"18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Sarcoma (protocolSection.conditionsModule.conditions)
• Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC) (protocolSection.conditionsModule.conditions)
• Mesothelioma (protocolSection.conditionsModule.conditions)
• Pheochromocytoma/Paraganglioma (PPGL) (protocolSection.conditionsModule.conditions)
• Pancreatic Ductal Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Ovarian Cancer (protocolSection.conditionsModule.conditions)
• Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
• Gastric Cancer (protocolSection.conditionsModule.conditions)
• Cholangiocarcinoma (protocolSection.conditionsModule.conditions)
• Bladder Cancer (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['1/Arm 1'], 'description': 'Participants will receive a single intravenous (IV) dose of \\[18F\\]FAPI-74 prior to PET/CT imaging.', 'name': '[18F]FAPI-74', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['1/Arm 1'], 'description': '18F-FDG PET/CT or PET/MRI imaging will be done per standard of care.', 'name': '[18F]FDG', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• [18F]FAPI-74 (protocolSection.armsInterventionsModule.interventions[].name)
• [18F]FDG (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.